1. ONTARGET Non-inferiority Comparison
Non-inferiority Margin
CV Death / MI / Stroke
(P=0.0008)
(HOPE Composite)
1,210 (14.1%) vs. 1,190 (13.9%) 0.99 ( )
Telmisartan better
Ramipril better
0.8
0.9
1.0
1.1
1.2
RR (95% CI)
Adapted from The ONTARGET Investigators. N Engl J Med 2008;358:

2. ONTARGET Discontinuation Rates
P<0.001
29.3
P=0.02
24.5 23
Adapted from ONTARGET Investigators.N Engl J Med 2008;358(15):

3. Priorities for Vascular and Renal Protection
Clinical Strategy
Target Population
Step 1: Initiate vascular protection
All people with diabetes
Step 2: Treat elevated BP
All people with diabetes whose BP remains ≥130/80 mm Hg after applying vascular protective measures
Step 3: Initiate renal protection
All people with diabetes who have proteinuria after applying vascular measures and after achieving BP <130/80 mm Hg
Adapted from Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Journal of Diabetes Sept 2008;32:suppl 1.